CACHET trial

CACHET trial

Comparison of Abciximab Complications with Hirulog (and back-up abciximab) Events Trial. A pilot study comparing abciximab + aspirin + heparin to bivalirudin/hirulog + aspirin + ad hoc abciximab as adjunctive pharmacotherapy for improving outcomes in percutaneous coronary revascularisation.
 
Conclusion
Bivalirubin was better than unfractionated heparin, with fewer bleeding complications.